Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In this issue of JAMA Dermatology, Fichel and colleagues1 have identified 3 clinical and immunological findings in bullous pemphigoid (BP) predictive of disease relapse within the first year of treatment. A statistically significant increase in the risk for relapse was observed in patients with more extensive cutaneous involvement prior to initiation of treatment, patients with dementia, and patients with an enzyme-linked immunosorbent assay (ELISA) test result showing serum levels of anti-BP180 autoantibodies of 23 U/mL or more on day 150. They also demonstrated a surprisingly high rate of success with the use of high-potency corticosteroids alone, coupled with reduction in measurable BP autoantibody levels.
Fine J. Clinical and Immunological Factors Associated With Bullous Pemphigoid Relapse. JAMA Dermatol. 2014;150(1):34. doi:10.1001/jamadermatol.2013.8090